Navigation Links
Medivation Announces Positive Top-Line Results From Phase 2 Dimebon Study in Huntington's Disease
Date:7/7/2008

g," said Lynn Seely, M.D., chief medical officer of Medivation. "These data are also important because they provide further support for our belief that Dimebon is exerting its benefits through a novel mechanism of action targeting mitochondrial dysfunction, a contributor to the loss of neuronal function in Huntington's disease. Medivation is committed to aggressively advancing development of Dimebon for patients and families devastated by Huntington's disease."

Full results from the Phase 2 study will be submitted for presentation at an upcoming scientific meeting.

About Huntington's Disease

Huntington's disease is a progressive, neurodegenerative disease that affects approximately 30,000 people in the U.S., with an additional 150,000 at risk, qualifying it as an orphan drug indication. It is caused by the death of specific brain cells and is characterized by the gradual development of involuntary muscle movement, progressive deterioration of cognitive processes and memory (dementia) and severe behavioral disturbances. There are currently no drugs approved by the U.S. Food and Drug Administration to treat this uniformly fatal genetic disorder.

About Dimebon

Dimebon is an orally-available small molecule that has been shown to inhibit brain cell death in preclinical models relevant to Alzheimer's disease and Huntington's disease, making it a potential treatment for these and other neurodegenerative diseases. The Company is currently enrolling patients in an international confirmatory Phase 3 clinical trial evaluating the efficacy and safety of Dimebon in patients with mild-to-moderate Alzheimer's disease. Preclinical data generated to date suggest that Dimebon operates through a novel mitochondrial mechanism of action.

Teleconference/Webcast Details

Medivation will host a teleconference at 5:00 p.m. Eastern Daylight Time today. To participate in the live call by telephone, please dial 877-419-6590 from the U.S. or 719-3
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Medivations MDV3100 Demonstrates Substantial PSA Reductions in First Patient Groups Treated in Phase 1-2 Hormone Refractory Prostate Cancer Trial
2. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
3. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
4. Medivations Dimebon(TM) Significantly Improved Thinking and Memory in Alzheimers Disease Patients Over One Year
5. Medivation Announces Presentation of MDV3100 Clinical Data in Patients With Castration-Resistant Prostate Cancer at 44th American Society of Clinical Oncology Annual Meeting
6. Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
7. Medivation Initiates Second Pivotal Phase 3 Trial of Dimebon(TM) in Patients With Alzheimers Disease
8. Medivation to Host Conference Call at 5 p.m. EDT Monday to Discuss Top-Line Phase 2 Study Results in Huntingtons Disease
9. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
10. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
11. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Onyx Pharmaceuticals to Webcast Analyst Briefing on Development Program 2Hand Surgeons Take Ethics into Their Own Hands 2Hand Surgeons Take Ethics into Their Own Hands 3Hand Surgeons Take Ethics into Their Own Hands 4Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 2Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug 3Restoring a natural root signal helps to fight a major corn pest 9462 1Restoring a natural root signal helps to fight a major corn pest 9462 2Restoring a natural root signal helps to fight a major corn pest 9462 3Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 1Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 2Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 3Rapid heating prepares energy saving zeolite for greater role in industrial separations 13338 4Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 1Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 2Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 3Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 4Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 5Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 6Consumer Reports Launches Online Hospital Ratings for More Than 3 400 U S Hospitals 53566 7
Other Medicine Technology:Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 2Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 3Autism Studies Presented at Mid-Atlantic Research Consortium Meeting 4New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 2New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 3New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 4New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 5New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 6New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 7New Data Shows Blood Pressure Reduction Therapy with BENICAR(R) and BENICAR HCT(R) Effectively Reduces Blood Pressure in Elderly Patients to Target Blood Pressure 8